Clinical trials using glypican-3 (GPC3) as a target are the most common CAT-T treatment for HCC, and its anti-tumor activity and safety have been preliminarily determined (46, 47); however, most of these trials are phase I trials that require further research and confirmation in larger-scale trials. The gene discussed is GPC3; the disease is hepatocellular carcinoma.